[go: up one dir, main page]

GB1202607A - Improvements in or relating to stable glucagon solutions and their preparation - Google Patents

Improvements in or relating to stable glucagon solutions and their preparation

Info

Publication number
GB1202607A
GB1202607A GB0536/68A GB153668A GB1202607A GB 1202607 A GB1202607 A GB 1202607A GB 0536/68 A GB0536/68 A GB 0536/68A GB 153668 A GB153668 A GB 153668A GB 1202607 A GB1202607 A GB 1202607A
Authority
GB
United Kingdom
Prior art keywords
solutions
preparation
relating
glucagen
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB0536/68A
Inventor
Jan Markussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Terapeutisk Laboratorium AS
Original Assignee
Novo Terapeutisk Laboratorium AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Terapeutisk Laboratorium AS filed Critical Novo Terapeutisk Laboratorium AS
Priority to GB0536/68A priority Critical patent/GB1202607A/en
Priority to DE19691900367 priority patent/DE1900367A1/en
Priority to BE726681D priority patent/BE726681A/xx
Priority to IT50089/69A priority patent/IT974528B/en
Priority to FR6900222A priority patent/FR2000114A1/en
Priority to NL6900460A priority patent/NL6900460A/xx
Priority to AT26769A priority patent/AT283600B/en
Publication of GB1202607A publication Critical patent/GB1202607A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1,202,607. Glucagen solutions. NOVO TERAPEUTISK LABORATORIUM A.S. 31 Dec., 1968 [10 Jan., 1968], No. 1536/68. Heading A5B. Stable, aqueous, injectable solutions of glucagon comprise from 0.1 to 5.0 mg/ml of glucagen and a stabilising and solubilising amount of an anionic, cationic or nonionic detergent, e.g. cetrimide, an alkyl aryl sulphonate or a polyoxyethylenealkyl ether/urea complex (others are mentioned). Preparation of the solutions is by simple admixture of the ingredients.
GB0536/68A 1968-01-10 1968-01-10 Improvements in or relating to stable glucagon solutions and their preparation Expired GB1202607A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB0536/68A GB1202607A (en) 1968-01-10 1968-01-10 Improvements in or relating to stable glucagon solutions and their preparation
DE19691900367 DE1900367A1 (en) 1968-01-10 1969-01-04 Stable glucagon solution and process for its preparation
BE726681D BE726681A (en) 1968-01-10 1969-01-09
IT50089/69A IT974528B (en) 1968-01-10 1969-01-09 STABLE SOLUTION OF GLUCAGON AND PROCEDURE FOR ITS PREPARATION
FR6900222A FR2000114A1 (en) 1968-01-10 1969-01-09 STABLE AQUEOUS SOLUTION FOR INJECTION OF GLUCAGON, AND PROCESS FOR ITS PREPARATION
NL6900460A NL6900460A (en) 1968-01-10 1969-01-10
AT26769A AT283600B (en) 1968-01-10 1969-01-10 Process for the preparation of a stable, aqueous, injectable glucagon solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0536/68A GB1202607A (en) 1968-01-10 1968-01-10 Improvements in or relating to stable glucagon solutions and their preparation

Publications (1)

Publication Number Publication Date
GB1202607A true GB1202607A (en) 1970-08-19

Family

ID=9723689

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0536/68A Expired GB1202607A (en) 1968-01-10 1968-01-10 Improvements in or relating to stable glucagon solutions and their preparation

Country Status (7)

Country Link
AT (1) AT283600B (en)
BE (1) BE726681A (en)
DE (1) DE1900367A1 (en)
FR (1) FR2000114A1 (en)
GB (1) GB1202607A (en)
IT (1) IT974528B (en)
NL (1) NL6900460A (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047160A1 (en) * 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO2011049713A2 (en) 2009-10-22 2011-04-28 Biodel Inc. Stabilized glucagon solutions
US8097698B2 (en) 1996-08-30 2012-01-17 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO2012059762A1 (en) 2010-11-03 2012-05-10 Arecor Limited Novel composition comprising glucagon
US9610329B2 (en) 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
FR3052071A1 (en) * 2016-06-07 2017-12-08 Adocia COMPOSITIONS IN THE FORM OF AQUEOUS INJECTABLE SOLUTION COMPRISING GLUCAGON AND A CO-POLYAMINOACID
WO2017211917A1 (en) * 2016-06-07 2017-12-14 Adocia Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
WO2017221026A1 (en) 2016-06-24 2017-12-28 Arecor Limited Novel composition
FR3061660A1 (en) * 2017-01-10 2018-07-13 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
FR3067247A1 (en) 2018-06-07 2018-12-14 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
WO2019110838A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
WO2019110836A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
WO2019110837A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
FR3074683A1 (en) * 2017-12-07 2019-06-14 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
US10335489B2 (en) 2012-01-09 2019-07-02 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid
US10449256B2 (en) 2013-02-12 2019-10-22 Adocia Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3083087A1 (en) 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
US11191812B2 (en) 2017-12-07 2021-12-07 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2643967A (en) * 1946-08-31 1953-06-30 Wallerstein Co Inc Concentrate of tyrothricin and its therapeutically active components
NL94376C (en) * 1958-04-28 1960-05-16 Nv Organon PROCESS FOR THE PREPARATION OF INJICIABLE GLACAGON PREPARATIONS WITH EXTENDED ACTION

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US8097698B2 (en) 1996-08-30 2012-01-17 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1999047160A1 (en) * 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
WO2011049713A2 (en) 2009-10-22 2011-04-28 Biodel Inc. Stabilized glucagon solutions
US9610329B2 (en) 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
WO2012059762A1 (en) 2010-11-03 2012-05-10 Arecor Limited Novel composition comprising glucagon
WO2012059764A1 (en) 2010-11-03 2012-05-10 Arecor Limited Novel composition comprising glucagon
JP2014501707A (en) * 2010-11-03 2014-01-23 アレコー リミテッド Novel composition comprising glucagon
US9023985B2 (en) 2010-11-03 2015-05-05 Arecor Ltd. Glucagon composition
US10335489B2 (en) 2012-01-09 2019-07-02 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid
US10449256B2 (en) 2013-02-12 2019-10-22 Adocia Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3052071A1 (en) * 2016-06-07 2017-12-08 Adocia COMPOSITIONS IN THE FORM OF AQUEOUS INJECTABLE SOLUTION COMPRISING GLUCAGON AND A CO-POLYAMINOACID
WO2017211918A1 (en) * 2016-06-07 2017-12-14 Adocia Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
US10485851B2 (en) 2016-06-07 2019-11-26 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
CN109562063A (en) * 2016-06-07 2019-04-02 阿道恰公司 The composition of the injectable aqueous solutions form of copolymerization amino acid comprising human glucagon and terminal graft
CN109562064A (en) * 2016-06-07 2019-04-02 阿道恰公司 The composition of injectable aqueous solutions form comprising human glucagon and statistics copolymerization amino acid
WO2017211917A1 (en) * 2016-06-07 2017-12-14 Adocia Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
US10383918B2 (en) 2016-06-07 2019-08-20 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid
WO2017221026A1 (en) 2016-06-24 2017-12-28 Arecor Limited Novel composition
FR3061660A1 (en) * 2017-01-10 2018-07-13 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
FR3074683A1 (en) * 2017-12-07 2019-06-14 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
WO2019110837A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
WO2019110836A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
US20190275156A1 (en) * 2017-12-07 2019-09-12 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
WO2019110838A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
CN111683675A (en) * 2017-12-07 2020-09-18 阿道恰公司 Compositions in the form of injectable aqueous solutions comprising human glucagon and a polyamino acid copolymer
US10987426B2 (en) 2017-12-07 2021-04-27 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
US11191812B2 (en) 2017-12-07 2021-12-07 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
FR3067247A1 (en) 2018-06-07 2018-12-14 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
FR3083087A1 (en) 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID

Also Published As

Publication number Publication date
NL6900460A (en) 1969-07-14
DE1900367A1 (en) 1969-09-04
BE726681A (en) 1969-07-09
IT974528B (en) 1974-07-10
FR2000114A1 (en) 1969-08-29
AT283600B (en) 1970-08-10

Similar Documents

Publication Publication Date Title
GB1202607A (en) Improvements in or relating to stable glucagon solutions and their preparation
GB1132086A (en) Novel pyrimidine derivatives
GB1423113A (en) Aqueous cholesterol standard
GB1244809A (en) Synergistic antibacterial compositions
GB1235801A (en) A process for the manufacture of rapidly-disintegrating solid dosage unit forms
GB1236710A (en) Stable alkali metal chlorite mixtures
ES363208A1 (en) Method of preparing morpholino cyano-acrylamides
GB1326327A (en) Process for the preparation of bis-p-chlorophenoxy-acetyl-urea
GB1289693A (en)
GB1222100A (en) Improvements relating to insulin solutions
ES357848A1 (en) Stable poliomyelitis vaccines
FR7536M (en)
GB1132583A (en) Pharmaceutical compositions containing cephalosporins
GB739800A (en) Aqueous pharmaceutical solutions of reserpine for parenteral administration
GB1241692A (en) Methine dyes and their use in light-sensitive silver halide elements
GB1302679A (en)
GB1180574A (en) Improvements in or relating to Injectable Thyroxine Preparations
GB1262971A (en) Stabilization of oestrogen-sulphate
GB1201423A (en) Improvements in or relating to iron salt-antibiotic compositions
GB1241832A (en) Cosmetic preparations
USD196300S (en) Picture hook or similar article
GB1382609A (en) Preparation of eburnamine alkaloid
USD234345S (en) Scale
GB1193650A (en) Improvements in and relating to Water-Soluble Cellulose Ether Compositions.
GB1081219A (en) Improvements in or relating to heald frames

Legal Events

Date Code Title Description
416 Proceeding under section 16 patents act 1949
PS Patent sealed
PLNP Patent lapsed through nonpayment of renewal fees